Beam Therapeutics Appoints Carole Ho, M.D., to Board of Directors
Cambridge, Mass. – Beam Therapeutics, a biotechnology company developing precision...
The human genome is made up of billions of nucleobases, or “bases,” represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
Starting with our founders and funders, we’re building a world-class team to develop precision genetic medicines through DNA and RNA base editing. Join us.
We are seeking a motivated individual to join our DNA editing platform group. The successful candidate will contribute to ourRead More
We are seeking a creative and motivated scientist to join our team in developing novel gene and cell therapies throughRead More
Beam seeks an experienced scientist to help us advance our New Opportunities programs, including precision therapeutic genome editing of patient-derivedRead More
26 Landsdowne Street
Cambridge, MA 02139